Multivariable Cox regression assessing HCT-CI and OS
| . | N . | HR (95% CI) . | P . |
|---|---|---|---|
| Entire nonmalignant cohort | |||
| 0 | 2512 | 1.00 | |
| 1-2 | 821 | 1.12 (0.93-1.34) | .218 |
| 3-4 | 556 | 1.33 (1.09-1.63) | .004 |
| ≥5 | 194 | 2.31 (1.79-2.96) | <.0001 |
| Aplastic anemia cohort | |||
| 0 | 726 | 1.00 | |
| 1-2 | 312 | 1.19 (0.87-1.64) | .275 |
| ≥3 | 299 | 2.06 (1.53-2.78) | <.0001 |
| Hemoglobinopathies cohort | |||
| 0 | 372 | 1.00 | |
| 1-2 | 157 | 0.46 (0.25-0.86) | .015 |
| ≥3 | 127 | 0.59 (0.29-1.21) | .153 |
| Immune deficiency cohort | |||
| 0 | 497 | 1.00 | |
| 1-2 | 174 | 1.37 (0.93-2.02) | .115 |
| ≥3 | 125 | 1.87 (1.21-2.88) | .0049 |
| Histiocytic disease cohort | |||
| 0 | 278 | 1.00 | |
| 1-2 | 77 | 0.89 (0.53-1.48) | .653 |
| ≥3 | 77 | 1.23 (0.78-1.92) | .374 |
| Bone marrow failure cohort | |||
| 0 | 320 | 1.00 | |
| 1-2 | 67 | 1.28 (0.76-2.17) | .358 |
| ≥3 | 83 | 1.80 (1.14-2.86) | .012 |
| Immunosuppressive conditioning | |||
| 0 | 451 | 1.00 | |
| 1-2 | 159 | 1.28 (0.78-2.11) | .315 |
| ≥3 | 143 | 1.58 (0.97-2.58) | .067 |
| Reduced-intensity conditioning | |||
| 0 | 1012 | 1.00 | |
| 1-2 | 408 | 1.00 (0.78-1.29) | .999 |
| ≥3 | 388 | 1.57 (1.24-2.00) | .0002 |
| Myeloablative conditioning | |||
| 0 | 1007 | 1.00 | |
| 1-2 | 239 | 1.26 (0.91-1.75) | .162 |
| ≥3 | 188 | 1.62 (1.18-2.22) | .003 |
| . | N . | HR (95% CI) . | P . |
|---|---|---|---|
| Entire nonmalignant cohort | |||
| 0 | 2512 | 1.00 | |
| 1-2 | 821 | 1.12 (0.93-1.34) | .218 |
| 3-4 | 556 | 1.33 (1.09-1.63) | .004 |
| ≥5 | 194 | 2.31 (1.79-2.96) | <.0001 |
| Aplastic anemia cohort | |||
| 0 | 726 | 1.00 | |
| 1-2 | 312 | 1.19 (0.87-1.64) | .275 |
| ≥3 | 299 | 2.06 (1.53-2.78) | <.0001 |
| Hemoglobinopathies cohort | |||
| 0 | 372 | 1.00 | |
| 1-2 | 157 | 0.46 (0.25-0.86) | .015 |
| ≥3 | 127 | 0.59 (0.29-1.21) | .153 |
| Immune deficiency cohort | |||
| 0 | 497 | 1.00 | |
| 1-2 | 174 | 1.37 (0.93-2.02) | .115 |
| ≥3 | 125 | 1.87 (1.21-2.88) | .0049 |
| Histiocytic disease cohort | |||
| 0 | 278 | 1.00 | |
| 1-2 | 77 | 0.89 (0.53-1.48) | .653 |
| ≥3 | 77 | 1.23 (0.78-1.92) | .374 |
| Bone marrow failure cohort | |||
| 0 | 320 | 1.00 | |
| 1-2 | 67 | 1.28 (0.76-2.17) | .358 |
| ≥3 | 83 | 1.80 (1.14-2.86) | .012 |
| Immunosuppressive conditioning | |||
| 0 | 451 | 1.00 | |
| 1-2 | 159 | 1.28 (0.78-2.11) | .315 |
| ≥3 | 143 | 1.58 (0.97-2.58) | .067 |
| Reduced-intensity conditioning | |||
| 0 | 1012 | 1.00 | |
| 1-2 | 408 | 1.00 (0.78-1.29) | .999 |
| ≥3 | 388 | 1.57 (1.24-2.00) | .0002 |
| Myeloablative conditioning | |||
| 0 | 1007 | 1.00 | |
| 1-2 | 239 | 1.26 (0.91-1.75) | .162 |
| ≥3 | 188 | 1.62 (1.18-2.22) | .003 |
For multivariable analysis on the entire cohort, the following variables were adjusted for in the final model: age, disease category, donor and graft source, recipient CMV status, and performance status. For multivariable analysis on subgroups by disease and conditioning intensity, the following variables were adjusted for in the final model: age, donor and graft source, recipient CMV status, and performance status.